ABBV vs MCK
ABBV: A diversified global biopharmaceutical leader with a strong footprint in immunology, neuroscience, and aesthetics, supported by a pipeline expanding into obesity. MCK: A global leader in pharmaceutical distribution and healthcare technology services, connecting biopharma, providers, and patients to improve care outcomes.
Side-by-side fundamentals
| Metric | ABBV | MCK | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $272.42 | $930.25 | |
| Market cap | $481.4B | $108.5B | |
| P/E as of 2026-10-08 | 76.54 | 24.91 | MCK lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2026 | n/a | 1.63 | |
| Net margin | +6.9% | +1.2% | ABBV higher |
| Gross margin FY2026, SEC XBRL | n/a | +3.6% | |
| Operating margin | +24.6% | +1.5% | ABBV higher |
| ROA | +3.2% | +5.8% | MCK higher |
| Debt / equity as of 2026-09-03 | 49.22 | 1.29 | MCK lower |
| Revenue growth (YoY) as of 2026-09-03 | +10.4% | +8.8% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | +13.4% | MCK higher |
| Dividend yield as of 2026-09-03 | +2.6% | +0.4% | ABBV higher |
| Dividend streak (yrs) SEC XBRL | 9 | 19 | MCK higher |
| Beta as of 2026-09-03 | 0.27 | 0.06 | |
| 1-year return as of 2026-10-08 close | +17.8% | +23.1% | MCK higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.